Holen Sie sich die Stockscreener-App
1.72
0.58%
-0.01
Vorhandelsmarkt:
1.72
Adial Pharmaceuticals Inc Aktie (ADIL) Neueste Nachrichten
Valuation Update: Will Adial Pharmaceuticals Inc benefit from geopolitical trends2026 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder - Sahm
Adial Pharmaceuticals Commends Introduction of H.R. 7091 to Expand Access to Alcohol Use Disorder Treatments for Veterans - Quiver Quantitative
Nearly 40% of veterans face AUD; new bill backs more therapy research - Stock Titan
Smart Money: Does Adial Pharmaceuticals Inc have a competitive edge2026 Trade Ideas & Daily Stock Trend Reports - baoquankhu1.vn
Nasdaq Moves: Whats the beta of Adial Pharmaceuticals Inc stock2026 Analyst Calls & Real-Time Volume Analysis - baoquankhu1.vn
Revenue per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
Tech Rally: Whats the fair value of Adial Pharmaceuticals Inc stockPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Is Adial Pharmaceuticals Inc. stock a smart buy before Fed meetingPortfolio Return Report & High Conviction Investment Ideas - Naître et grandir
Key facts: Adial Pharmaceuticals reports $7.98M annual loss; 2025 results show regulatory progress - TradingView
Adial Pharmaceuticals (ADIL) Enhances Financial Position and Cli - GuruFocus
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) outlines AD04 advances, Europe deal and Nasdaq win - Stock Titan
Adial Pharmaceuticals 10-K: $(7.98M) Net Loss, $(11.93) EPS; Cash into H2 2026 - TradingView
Adial Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ADIL SEC FilingsAdial Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Adial Pharmaceuticals signs framework deal with Molteni for Europe By Investing.com - Investing.com Canada
Adial Pharmaceuticals (ADIL) Plans European Expansion for AD04 w - GuruFocus
Adial Pharmaceuticals signs exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe - marketscreener.com
Adial Pharmaceuticals signs framework deal with Molteni for Europe - Investing.com
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks
Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones - TradingView
Adial (NASDAQ: ADIL) outlines AD04 Europe deal framework with Molteni - Stock Titan
Adial Pharmaceuticals, Inc. Enters into A Collaboration Framework Agreement with Molteni Farmaceutici - marketscreener.com
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - ADVFN Ltd
Adial Pharmaceuticals, IncWarrant (NQ: ADILW - The Chronicle-Journal
Adial Pharmaceuticals Secures Exchange Listing Amid Regulatory Tailwinds - AD HOC NEWS
ADIL Should I Buy - Intellectia AI
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 87.7% - Defense World
ADIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - The Globe and Mail
ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus
Key facts: Adial Pharmaceuticals meets Nasdaq bid requirement; advances AD04 to Phase 3 trial - TradingView
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Bitget
Adial Pharmaceuticals regains full compliance with Nasdaq listing requirement - marketscreener.com
Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView
Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement - TradingView
Adial Pharmaceuticals (ADIL) regains Nasdaq compliance, highlights AD04 Phase 3 path - Stock Titan
Adial Pharmaceuticals eyes single pivotal trial path for AD04 - Investing.com India
Adial Pharmaceuticals eyes single pivotal trial path for AD04 By Investing.com - Investing.com Australia
Adial Pharmaceuticals stock rises on FDA policy shift By Investing.com - Investing.com South Africa
Adial Pharmaceuticals stock rises on FDA policy shift - Investing.com
Adial Pharmaceuticals (ADIL) Sees Potential in FDA's New Approva - GuruFocus
Portfolio Shifts: Can Adial Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Volume & Consistent Profit Alerts - baoquankhu1.vn
Adial Pharmaceuticals at a Strategic Crossroads () - aktiencheck.de
ADIL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Adial Pharmaceuticals to Present at Healthcare Conference - National Today
Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight Alkermes, Teva Pharma, Biocorrx, Inc., Adial Pharma, ADDEX THERAPEUTICS - Mena FN
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):